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Introduction
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum 
of liver disease encompassing steatosis, nonalcoholic steatohep-
atitis (NASH), and cirrhosis and is increasingly recognized as the 
leading cause of liver dysfunction in Western societies. NAFLD is 
strongly associated with obesity, dyslipidemia, insulin resistance, 
and diabetes mellitus (1–4) and is considered to be a hepatic man-
ifestation of the metabolic syndrome (5).
Steatosis sensitizes the liver to the induction of inflammation 
by a second pathogenic insult that promotes oxidative stress and 
activation of the inflammasome, resulting in steatohepatitis (6, 7). 
Oxidative stress may occur as a consequence of dietary or envi-
ronmental factors on the background of the metabolic syndrome 
(8). Persistent inflammation in response to liver injury is the crit-
ical factor that drives progression to fibrosis, cirrhosis, and hepa-
tocellular carcinoma (9). Inflammation at any site, including the 
liver, is the result of an accumulation of leukocytes organized into 
an inflammatory infiltrate. For this to occur, leukocytes must be 
recruited from the circulation by interactions with endothelium 
and positioned within the tissue (10).
Vascular adhesion protein-1 (VAP-1) is a 170-kDa homodi-
meric type 2 transmembrane sialoglycoprotein that has a short 
cytoplasmic tail with no known signal sequence, a single trans-
membrane segment, and a large extracellular domain (11). VAP-1 
is constitutively expressed on human hepatic endothelium and 
supports lymphocyte adhesion and transendothelial migration 
across primary hepatic sinusoidal endothelium in vitro and in sev-
eral models of liver inflammation in vivo (12–15). Cloning of VAP-1 
revealed it to be a copper-dependent semicarbazide-sensitive 
amine oxidase (SSAO) [E.C.1.4.3.6] known as amine oxidase cop-
per–containing 3 (AOC3), which catalyzes the oxidative deamina-
tion of exogenous and endogenous primary amines (such as those 
generated from sarcosine, creatinine, and adrenaline), resulting in 
the generation of aldehyde, ammonia, and H2O2 (16). These prod-
ucts activate NFκB-dependent chemokine secretion and adhesion 
molecule expression in liver endothelium (17, 18) and may also 
initiate and propagate oxidative stress following the conversion 
of H2O2 to hydroxyl free radicals. VAP-1 is also found in adipo-
cytes and smooth muscle cells, and provision of SSAO substrates 
to these cells in vitro has insulin-like effects on their metabolism, 
which is mediated via PI 3-kinase activation by H2O2 (19–21).
Nonalcoholic fatty liver disease (NAFLD) encompasses a range of manifestations, including steatosis and cirrhosis. 
Progressive disease is characterized by hepatic leukocyte accumulation in the form of steatohepatitis. The adhesion molecule 
vascular adhesion protein-1 (VAP-1) is a membrane-bound amine oxidase that promotes leukocyte recruitment to the liver, 
and the soluble form (sVAP-1) accounts for most circulating monoamine oxidase activity, has insulin-like effects, and can 
initiate oxidative stress. Here, we determined that hepatic VAP-1 expression is increased in patients with chronic liver disease 
and that serum sVAP-1 levels are elevated in patients with NAFLD compared with those in control individuals. In 4 murine 
hepatic injury models, an absence or blockade of functional VAP-1 reduced inflammatory cell recruitment to the liver and 
attenuated fibrosis. Moreover, disease was reduced in animals expressing a catalytically inactive form of VAP-1, implicating 
enzyme activity in the disease pathogenesis. Within the liver, hepatic stromal cells expressed functional VAP-1, and 
evaluation of cultured cells revealed that sVAP-1 promotes leukocyte migration through catalytic generation of ROS, which 
depended on VAP-1 enzyme activity. VAP-1 enhanced stromal cell spreading and wound closure and modulated expression of 
profibrotic genes. Together, these results link the amine oxidase activity of VAP-1 with hepatic inflammation and fibrosis and 
suggest that targeting VAP-1 has therapeutic potential for NAFLD and other chronic fibrotic liver diseases.
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provide evidence that VAP-1 is a potential therapeutic target in 
NAFLD and other chronic inflammatory liver diseases.
Results
Circulating serum [sVAP-1] is significantly elevated in human NAFLD 
and is independently associated with the presence of liver disease. 
Because circulating levels of sVAP-1 are significantly elevated in 
the serum of patients with chronic inflammatory liver diseases 
and in those with complications of the metabolic syndrome (23, 
26–30), we investigated whether sVAP-1 levels in patients with the 
metabolic syndrome are associated with the presence and severity 
of NAFLD. We compared serum levels of sVAP-1 in 144 patients 
with biopsy-proven NAFLD and 74 control patients matched for 
age and metabolic phenotype but without biochemical or radio-
logical evidence of liver disease (Table 1). The cohorts were well 
matched for age and BMI. A larger proportion of NAFLD patients 
were male than in the control cohort, but sVAP-1 levels were 
higher in females when compared with those in males in both 
cohorts. An increased number of patients in the NAFLD cohort 
had hypertension and diabetes, which is unsurprising, given the 
close association between these conditions and NAFLD. A large 
proportion of both cohorts had impaired glucose tolerance. Cho-
lesterol levels were similar in each cohort, but those with NAFLD 
had higher triglyceride levels.
We found that soluble VAP-1 levels were significantly increased 
in the NAFLD group when compared with those in controls 
matched for age and metabolic phenotype (median, 837 ng/ml 
[interquartile range {IQR}, 655–1,051 ng/ml] versus 256 ng/ml 
[IQR, 212–308 ng/ml], P < 0.0001; Figure 1A and Table 1). sVAP-
1 levels in the NAFLD cohort correlated with the amine oxidase 
activity of the patients’ serum (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI73722DS1). Univariate analysis showed that the homeostatic 
model of insulin resistance (HOMA-IR) (rs = 0.3, P = 0.03) and 
diabetic status (rs = 0.32, P = 0.0002) were correlated with sVAP-
1 in the NAFLD cohort (Supplemental Table 1), whereas fibrosis 
A soluble form of VAP-1 (sVAP-1) accounts for nearly all of the 
circulating amine oxidase activity in humans (22–24). The level of 
sVAP-1 in serum is regulated in part by changes in plasma insulin 
(25), and sVAP-1 levels are elevated in a number of inflammatory 
conditions (23, 26). Our group has previously shown that circu-
lating levels of sVAP-1 are substantially elevated in the serum of 
patients with several chronic inflammatory liver diseases (alco-
holic liver disease, primary biliary cirrhosis, primary sclerosing 
cholangitis), but not in rheumatoid arthritis or inflammatory 
bowel disease. VAP-1 is shed from the hepatic vasculature and adi-
pose tissue, and measurement of VAP-1 levels in hepatic and por-
tal veins suggests that the liver is a major source of sVAP-1 (23, 26). 
Elevated serum sVAP-1 levels have also been reported in patients 
with diabetes, obesity, and complications of the metabolic syn-
drome such as atherosclerosis and congestive heart failure (27–31).
These observations led us to propose that VAP-1 may have an 
important role in the progression of NAFLD and establishment of 
chronic liver disease (CLD). Here, we show that hepatic expres-
sion of VAP-1 is increased in human NAFLD in association with 
markedly elevated serum levels of sVAP-1 when compared with 
those in controls matched for age, sex, and metabolic phenotype. 
We provide evidence that VAP-1 promotes the progression of 
steatohepatitis, because VAP-1–deficient mice (Aoc3–/–) and WT 
animals treated with a neutralizing Ab were protected from the 
development of severe steatohepatitis and onset of fibrosis in 3 
murine models of steatohepatitis and a carbon tetrachloride (CCl4) 
model of fibrosis. In particular, VAP-1 deficiency protects against 
the accumulation of intrahepatic T cells, NKT cells, and myeloid 
subsets. Furthermore, through the use of mice expressing catalyt-
ically inactive VAP-1 as a consequence of an Aoc3 point mutation 
knock-in, we demonstrate that the amine oxidase activity of VAP-1 
is crucial for the accumulation of these effector immune cells and 
the establishment of fibrosis. We demonstrate that hepatic stromal 
cells express VAP-1, which can promote the expression of fibrotic 
markers and accelerate wound healing. These findings strongly 
implicate VAP-1 in the pathogenesis of fibrotic liver disease and 
Table 1. Comparison of physical and biochemical parameters associated with the NAFLD and control cohorts
NAFLD cohort, Median (IQR) Control cohort, Median (IQR) P value (Mann-Whitney U test)
Total Males Females Total Males Females Total Males Females
Number 133 85 48 74 20 54 NA NA NA
Age 51.0 (39.0–59.0) 47.0 (32.6–58.5) 53.0 (46.0–59.8) 48.0 (41.0–53.0) 47.5 (41.0–55.8) 49.0 (41.0–53.0) 0.2 0.9 0.008
BMI (kg/m2) 35.0 (31.8–38.0) 34.0 (31.0–37.0) 35.0 (32.0–39.1) 33.4 (31.2–36.4) 32.1 (30.5–34.7) 33.7 (31.6–36.7) 0.2 0.2 0.07
Hypertension (%) 46.6 44.7 50.0 33.8 65.0 22.2 NA NA NA
Diabetes (%) 43.6 42.4 45.8 28.4 40.0 24.1 NA NA NA
Cholesterol (mmol/l) 5.4 (4.7–6.3) 5.4 (4.5–6.2) 5.5 (4.9–7.0) 4.9 (4.3–5.6) 4.9 (4.4–5.9) 4.9 (4.3–5.6) 0.01 0.4 0.002
Triglycerides (mmol/l) 2.2 (1.1–3.1) 2.4 (1.5–3.3) 1.9 (1.5–2.6) 1.2 (0.8–1.8) 1.5 (1.0–1.8) 1.2 (0.8–1.8) <0.0001 0.003 <0.0001
Bilirubin (μmol/l) 10.0 (7.0–13.0) 11.0 (9.0–14.5) 8.0 (6.0–11.0) 4.0 (3.0–6.0) 6.0 (4.5–10.5) 4.0 (3.0–5.0) <0.0001 0.001 <0.0001
Albumin (g/l) 45.0 (42.0–47.0) 45.0 (43.0–47.0) 44.0 (41.0–46.0) 43.0 (42.0–45.0) 44.0 (43.0–45.0) 43.0 (42.0–45.0) 0.004 0.06 0.7
ALT (IU/l) 67.0 (46.0–123.0) 71.0 (47.5–126.0) 56.0 (42.0–101.0) 9.0 (7.0–11.0) 10.0 (8.0–14.5) 8.0 (6.0–10.0) <0.0001 <0.0001 <0.0001
AST (IU/l) 47.0 (33.3–72.8) 48.5 (34.0–73.3) 42.0 (30.8–67.5) 15.0 (11.3–20.0) 16.0 (13.0–20.0) 15.0 (11.0–18.0) <0.0001 <0.0001 <0.0001
GGT (IU/l) 89.0 (52.0–149.5) 93.0 (54.0–153.0) 82.5 (37.8–149.3) 22.0 (16.0–30.0) 27.0 (20.0–34.0) 21.0 (15.0–29.0) <0.0001 <0.0001 <0.0001
sVAP-1 (ng/ml) 837.0  
(655.0–1,051.0)
754.0  
(630.0–1,027.5)
866.0  
(745.0–1,186.3)
256.0  
(212.0–308.0)
256.0  
(212.0–300.0)
256.0  
(212.0–317.0)
<0.0001 <0.0001 <0.0001
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The area under the receiver operat-
ing curve (AUROC) to predict his-
tological NASH by serum sVAP-1 in 
our cohort was 0.82 (95% CI, 0.74–
0.90), and a cutoff level of greater 
than 793.5 ng/ml estimated NASH 
with a sensitivity of 67.7% and spec-
ificity of 89.7% (data not shown).
We determined the clinical and 
biochemical characteristics of our 
NAFLD cohort that were indepen-
dently associated with the pres-
ence of significant fibrosis (Kleiner 
classification F ≥2; ref. 32) on liver 
biopsy (Figure 1F) using univariate 
descriptive statistics followed by 
multiple logistic regression analysis with backward elimination 
(Table 3 and Supplemental Table 2). This revealed sVAP-1 to 
be a good predictor of the presence of significant fibrosis (F ≥2) 
(β coefficient, 0.32, P = 0.001). The AUROC to predict significant 
fibrosis (F ≥2) by serum sVAP-1 was 0.71 (95% CI, 0.62–0.79), 
and a cutoff level of greater than 1,018 ng/ml estimated F ≥2 with 
a sensitivity of 45.2% and specificity of 91.5% (data not shown).
Hepatic VAP-1 expression is increased in human CLD. We inves-
tigated hepatic expression of VAP-1 in the spectrum of NAFLD 
by immunohistochemistry (Figure 2A). In normal liver and in 
patients with simple steatosis, we observed that VAP-1 expres-
sion was confined to vascular structures, portal vessels, central 
veins, and sinusoids. In patients with steatohepatitis, we detected 
more pronounced VAP-1 staining in septal areas when compared 
with staining in normal liver tissue or simple steatosis, which was 
partly associated with neovessels in the hepatic scar (Figure 2A). 
We extended our study to other end-stage CLDs, namely primary 
biliary cirrhosis, primary sclerosing cholangitis, and alcoholic 
liver disease. In all 3 diseases, immunohistochemistry demon-
strated increased staining of VAP-1 in fibrotic septa (Figure 2B). 
Multicolor confocal microscopy showed that rather than having 
a predominantly endothelial (CD31+) distribution, VAP-1 stained 
stage was the only factor independently associated with sVAP-1 
after multiple logistic regression modeling (Table 2). To date, 17 
patients from the NAFLD cohort have died (8 from cancer: 4 hepa-
tocellular carcinoma, 1 esophageal cancer, 1 colon cancer, 1 breast 
cancer, and the eighth patient died from a combination of breast 
cancer and Ewing’s sarcoma), 13 of whom were cirrhotic. The 
concentration of sVAP-1 in those who subsequently died (median, 
1,287 ng/ml; IQR, 1,243–2,116 ng/ml) was significantly higher 
(P = 0.000107 by Mann-Whitney U test) than that in patients who 
are still alive (median, 814 ng/ml; IQR, 653–1,001 ng/ml).
Circulating sVAP-1 correlates with disease severity and is pre-
dictive of NASH and the presence of significant fibrosis on biopsy in 
NAFLD. The histological spectrum of NAFLD includes simple 
steatosis, steatohepatitis with different levels of liver injury, and 
fibrosis leading to cirrhosis. We assessed sVAP-1 levels in rela-
tion to the presence or absence of hepatocyte ballooning, lobular 
inflammation, and fibrosis and found significantly higher levels 
when each of these histological features was present (Figure 1, 
B–D). Furthermore, we found that sVAP-1 levels were significantly 
increased in patients with NASH (defined as steatosis plus lobular 
inflammation, hepatocyte ballooning, and/or fibrosis) compared 
with those in patients with simple steatosis (Figure 1E, P < 0.0001). 
Figure 1. Serum sVAP-1 is elevated in 
patients with NAFLD and correlates 
with histological markers of liver injury. 
(A) sVAP-1 levels in patients with NAFLD 
(n = 133) were compared with those in a 
control cohort of patients with metabolic 
syndrome but no evidence of liver injury 
(n = 74). (B–E) Elevated sVAP-1 levels in 
patients with NAFLD were associated 
with lobular inflammation (B), hepatoc-
yte ballooning (C), fibrosis (D), and NASH 
(E). (F) sVAP-1 concentrations in patient 
serum increased with the fibrosis stage 
as determined from biopsy samples 
(Kleiner classification). (A–E) P values 
were calculated by Mann-Whitney U test; 
(F) Kruskal-Wallis test (P = 0.0003) and 
Cuzick trend test (P ≤ 0.0001); P’ was 
calculated by Mann-Whitney U test with 
Bonferroni’s correction.
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of sVAP-1 were attenuated by the VAP-1 enzyme inhibitor BEA or 
by the removal of H2O2 by catalase (Figure 3H). The inhibition of 
catalysis or removal of H2O2 reduced the number of cells migrat-
ing to sVAP-1 by more than 50%, suggesting that the promigratory 
action of sVAP-1 is, in part, a consequence of the catalytic genera-
tion of ROS by VAP-1 enzyme activity. The addition of the GPCR 
inhibitor pertussis toxin (PTx) reduced the number of migrating 
cells to a similar degree, suggesting that VAP-1–induced migration 
is dependent on GPCR signaling, consistent with studies showing 
that ROS activate the GPCR (36). Exposure to VAP-1 did not lead 
to activation of leukocyte β1 or β2 integrins or changes in the sur-
face expression of the chemokine receptors CCR1-10, CXCR1-7, or 
CX3CR1 (data not shown).
These human data demonstrated that enzymatically active 
VAP-1 expressed by aHSCs is upregulated in the diseased liver 
and is capable of modulating leukocyte recruitment. This led us to 
study the role of VAP-1 in liver fibrogenesis in vivo.
VAP-1 deficiency attenuates CCl4-induced hepatic fibrosis. We 
used a CCl4 model to induce hepatic injury in WT (C57BL/6) mice, 
VAP-1–KO (Aoc3–/–) mice, and WT mice that received weekly doses 
of a monoclonal anti–VAP-1 Ab (BTT-1029). Control animals 
received mineral oil (MO) alone. One group of animals was sacri-
ficed after 8 weeks of CCl4 treatment and a second group following 
an additional 4-week period of resolution during which CCl4 treat-
ment was stopped. We found that untreated Aoc3–/– animals had an 
overtly normal phenotype with macroscopically and microscopi-
cally normal livers, consistent with previous reports (37).
In line with previous studies, we detected bridging fibrosis by 
picosirius red staining at 8 weeks in WT animals, with significant 
fibrosis resolution 4 weeks after stopping CCl4 treatment (Figure 
4A). Alanine aminotransferase (ALT) levels were comparable 
between WT, Aoc3–/–, and Ab-treated animals given CCl4, suggest-
ing that the absence of VAP-1 did not diminish the degree of initial 
liver injury (Figure 4B). This finding was similar to that seen for 
blockade of a related amine oxidase, lysyl oxidase–like protein-2 
(LOXL2), in a CCl4-induced injury model (38).
We found that Aoc3–/– mice and WT animals treated with 
anti–VAP-1 Ab had significantly less fibrosis at 8 weeks, as demon-
strated by picosirius red staining and reduced staining for α-SMA 
(Figure 4, C and D). Four weeks after stopping CCl4, we observed 
that fibrosis was greatly reduced in all animals, although WT ani-
mals had significantly more extensive picosirius red staining com-
pared with that seen in MO-treated control mice (Figure 4C). We 
confirmed an increase in fibrosis in the CCl4-treated WT mice rel-
ative to that in Aoc3–/– mice at 8 weeks by real-time quantitative 
reverse transcription PCR (qRT-PCR) of whole liver for collagen 1 
(Col1a1) and α-SMA (Acta2), and there was a trend toward a 
α-SMA+ and CD90+ stromal cells within the NASH liver with mark-
edly increased VAP-1 expression throughout the expanded space 
of Disse (Figure 2D). In contrast, we did not detect VAP-1 in biliary 
epithelial cells (EpCAM+) or hepatocytes (CK18+) (Figure 2C).
Stromal cells express VAP-1, which promotes amine oxidase–depen-
dent lymphocyte migration in vitro. To determine whether the VAP-1 
protein could be synthesized by stromal cells, we isolated activated 
hepatic stellate cells (HSCs) from nonfibrotic human tissue and in 
vivo–activated liver myofibroblasts (aLMFs) from end-stage chron-
ically diseased human liver tissue. Both cell types had detectable 
VAP-1 protein localized to cytoplasmic vesicles with little mem-
branous expression (Figure 3A), and these cells were capable of de 
novo synthesis of AOC3 mRNA at levels that were comparable to 
those in hepatic sinusoidal endothelial cells (HSECs). We observed 
similar levels in the HSC cell line LX2, allowing us to use this cell 
line to model HSC responses (Figure 3B). Expression of AOC3 
mRNA in LX2 cells was upregulated by PDGF-BB and TGF-β1 (Fig-
ure 3C), consistent with increased expression of VAP-1 in fibrotic 
tissues. The addition of recombinant VAP-1 (rVAP-1) had no effect 
on AOC3 expression in LX2, indicating that transcription of VAP-1 
is not modulated by extracellular VAP-1 in this system.
We detected sVAP-1 in conditioned media from in vitro– 
activated HSC (aHSC) and aLMF cultures and confirmed enzyme 
activity by detecting H2O2 generation in response to the SSAO sub-
strate benzylamine (Figure 3D). This activity could be blocked by 
the SSAO inhibitor 2-bromoethylamine (BEA), but not by the lysyl 
oxidase–specific (LOX-specific) inhibitor β-aminopropionitrile 
(β-APN). The release of VAP-1 from the stromal compartment in 
vitro and the increased circulating levels of sVAP-1 in patients with 
steatohepatitis prompted us to investigate whether sVAP-1 could 
provide a promigratory signal for leukocytes. Multicolor confocal 
microscopy of tissue sections taken from the liver of patients with 
NASH cirrhosis demonstrated a close association between VAP-1+ 
stromal cells and infiltrating leukocytes (Figure 3E). Conditioned 
media from in vitro–cultured aHSCs promoted the migration of 
lymphocytes in Boyden chamber assays, and the addition of a 
function-blocking anti–VAP-1 Ab (TK8-14) reduced their migra-
tory capacity by more than 50% (Figure 3F). In parallel studies, 
highly purified human sVAP-1 induced dose-dependent migration 
of peripheral blood lymphocytes in Boyden chamber assays with 
a maximal response between 10 and 100 ng/ml (Figure 3G) that 
was comparable to that seen with 10 ng/ml CXCL12, a potent lym-
phocyte chemotactic factor. The related amine oxidase LOX has 
been shown to promote the migration of smooth muscle cells and 
monocytes through the action of H2O2 (33, 34), and a recent study 
in zebrafish reported that H2O2 produced by an unspecified amine 
oxidase promotes leukocyte recruitment during wound healing 
(35). This led us to investigate whether the promigratory effects 
Table 2. Parameters that independently correlated with sVAP-1 
concentrations following multivariate analysis
Variable β coefficient P value
Fibrosis stage 0.31 0.02
Steatosis grade 0.23 0.08
HOMA-IR 0.22 0.09
Table 3. Parameters that independently correlated with 
significant fibrosis (Kleiner score F ≥2) following multivariate 
analysis
Variable β coefficient P value
Lobular inflammation 0.638 0.0000001
sVAP-1 0.32 0.001
Hypertension 0.20 0.01
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mine whether leukocyte infiltration 
preceded fibrosis, we quantified lym-
phocyte and monocyte subsets in the 
livers of WT and Aoc3–/– animals prior 
to CCl4 administration (base), follow-
ing 2, 4, or 8 weeks of CCl4, and at 12 
weeks (resolution). Lymphocyte recruit-
ment occurred within the first 2 weeks, 
whereas myeloid cells peaked at 8 weeks 
following injury (Figure 5, A–C). There 
was a significant reduction in the abso-
lute number of all subsets in the livers of 
Aoc3–/– mice compared with that seen in 
WT animals receiving the same dose of 
CCl4. The numbers of cells detected in 
the WT livers increased progressively 
up to the 8-week treatment time point 
and returned to the levels observed 
for the Aoc3–/– group 4 weeks after ces-
sation of CCl4. At the early (2-week) time point, we observed a 
marked reduction in the numbers of CD8+ T cells and CD19+ 
B cells in Aoc3–/– animals and significantly fewer CD4+ T cells, and 
we detected NK1.1+ and CD3+NK1.1+ NKT cells at 4 weeks, 8 weeks, 
and 4 weeks, respectively (Figure 5, A and B). Infiltration with mac-
rophages and myeloid cells peaked later at 8 weeks and was signifi-
cantly reduced in Aoc3–/– animals at both the 4-week and 8-week 
time points (Figure 5, A and C). We observed no significant differ-
ences in the numbers of cells within the WT and Aoc3–/– livers prior 
to the administration of CCl4 (Figure 5A, Base). Our finding that 
leukocytes were recruited during the first 2 weeks following CCl4 
decrease in Col1a1 and Acta2 in WT mice that received Ab (Figure 
4, E and F). In all groups, mRNA levels for these markers of fibrosis 
returned to those seen in mice receiving MO following 4 weeks of 
resolution. The extent of picosirius red and α-SMA staining was 
not significantly different between the 8- and 12-week time points 
in the animals receiving BTT-1029, suggesting that the Ab offers 
protection against CCl4-induced fibrosis (Figure 4, C and D).
VAP-1 deficiency attenuates leukocyte infiltration into the liver 
during fibrogenesis. VAP-1 promotes leukocyte recruitment to the 
liver (39), suggesting a mechanism to explain the attenuated fibro-
sis observed in the absence of functional VAP-1. In order to deter-
Figure 2. Expression of VAP-1 is increased in 
liver tissue from patients with evidence of 
liver disease and localizes to hepatic stromal 
cells. (A) Immunohistochemical detection 
of VAP-1 (brown) in liver sections taken from 
patients across the spectrum of NAFLD 
(mild-to-moderate-to-severe steatosis and 
cirrhosis). Sections were counterstained 
with hematoxylin (blue). Scale bars: 50 μm. 
(B) VAP-1 staining (red) was detected in 
sinusoids and fibrotic septa in CLD (primary 
biliary cirrhosis, top panel; primary sclerosing 
cholangitis, middle panel; and alcoholic liver 
disease, lower panel). Scale bars: 200 μm. (C) 
Confocal fluorescence microscopy with dual 
fluorescent staining for VAP-1 (green) and 
cell-specific markers in cirrhotic liver (red). 
VAP-1 was present on some CD31+ endothe-
lial cells, but was predominantly associated 
with the stromal cell markers α-SMA and 
CD90. VAP-1 did not colocalize with markers 
of cholangiocytes (EpCAM) or hepatocytes 
(CK18). Scale bars: 50 μm. (D) Multicolor 
confocal microscopy showed increased VAP-1 
expression levels (green) in the expanded 
space of Disse in the sinusoids of NASH livers 
(lower panel) when compared with levels in 
normal livers (upper panel). The endothelial 
marker CD31 is shown in red (coexpression is 
yellow). Scale bars: 20 μm.
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Figure 3. Isolated human hepatic stromal cells express functional VAP-1 capable of driving lymphocyte migration in vitro. (A) VAP-1 was detected in 
isolated human aHSCs (left) and aLMFs (right) (DAPI blue). Scale bars: 50 μm. (B) AOC3 mRNA was expressed by HSECs, aLMFs, aHSCs (4 independent 
patient isolates each) and by the HSC cell line LX2 (3 repeats) at similar levels (dotted line represents negative controls). (C) Expression of AOC3 could 
be induced following a 24-hour incubation with PDGF-BB or TGF-β1 (both at 10 ng/ml) but not with rVAP-1 (500 ng/ml). Data represent 2 independent 
experiments measured in triplicate. (D) Amine oxidase activity of aHSCs (n = 4 isolates) in the absence and presence of VAP-1/LOX inhibitor BEA or 
the LOX-specific inhibitor 2-APN. (E) CD3+ lymphocytes (left) and CD68+ macrophages (right) were closely associated with VAP-1+ vessels and stroma in 
cirrhotic livers. Scale bars: 50 μm. (F) Conditioned media from primary cell cultures of aHSCs (n = 3 isolates) promoted VAP-1–dependent migration of 
peripheral blood lymphocytes in modified Boyden chamber assays. (G) Highly purified sVAP-1 induced the migration of peripheral blood lymphocytes in 
modified Boyden chamber assays in vitro (n = 3 lymphocyte preparations, 12 random fields/sample). (H) Lymphocyte migration was induced by 100 ng/
ml sVAP-1 and is shown compared with the baseline response to media alone (n = 3 lymphocyte preparations; 12 random fields per sample). Data were 
calculated by 1-way ANOVA with Tukey’s post-hoc test (C, G, and H), paired Student’s t test (D), and Mann-Whitney U test (F). *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001.
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administration prior to the development of fibrosis (Figure 5B) is 
consistent with reports implicating them in fibrogenesis (40).
VAP-1 promotes the development of severe steatohepatitis in a 
murine methionine choline–deficient diet. Mice fed a methionine 
choline–deficient (MCD) diet develop liver injury with histology 
similar to that of human NASH including steatosis, inflamma-
tory cell infiltration, and early fibrosis (41). To further investigate 
the role of VAP-1 in the development of liver disease in vivo, we 
administered an MCD diet for 6 weeks to 3 groups of 6 mice: (a) 
WT (C57BL/6), (b) Aoc3–/–, and (c) WT mice treated with weekly 
monoclonal anti–VAP-1 Ab 
started 1 week prior to the diet 
(WT plus BTT-1029). At sacrifice, 
we found that serum ALT levels 
were elevated in all mice, with no 
significant differences between 
the 3 groups, similar to that seen 
for the CCl4 model (Figure 6A). 
Bilirubin levels were raised in the 
Ab-treated group compared with 
those in the WT and KO animals, 
but we observed no differences 
in weight loss or blood glucose 
levels in these groups (Supple-
mental Figure 2). Low-power 
microscopy of H&E-stained liver 
sections demonstrated macrove-
sicular steatosis in association 
with inflammatory foci in WT 
mice (Figure 6B). We found sig-
nificantly fewer inflammatory 
foci in the livers of mice treated 
with anti–VAP-1 Ab and in Aoc3–/– 
mice compared with those found in WT mice (Figure 6C). Steato-
sis determined by Oil red O staining was present in all mice, but 
was less extensive in anti–VAP-1–treated mice and particularly 
reduced in Aoc3–/– mice (Figure 6, D and E). This finding was unex-
pected, because SSAO activity modulates glucose uptake, whereas 
the MCD diet model does not induce insulin resistance.
Aoc3–/– mice show a reduction in intrahepatic CD4+ and NKT 
cell populations in response to MCD diet–induced steatohepati-
tis. Having demonstrated by histology that there was a reduc-
tion in inflammatory infiltrates in Aoc3–/– or anti–VAP-1–treated 
Figure 4. VAP-1 contributes to scar 
formation in CCl4-induced murine 
fibrosis. (A) Picrosirius red staining 
of liver from WT mice receiving 
an 8-week treatment of MO, CCl4, 
or CCl4 plus a function–blocking 
anti–VAP-1 Ab (WT CCl4 + Ab) or liver 
from Aoc3–/– mice that received CCl4 
(Aoc3–/– CCl4). Lower panels depict 
the same experimental groups fol-
lowing an additional 4 weeks of reso-
lution after stopping CCl4 at 8 weeks. 
Scale bars: 200 μm. (B) Serum ALT 
levels and (C and D) sirius red (C) 
and α-SMA (D) staining following 
8 weeks of vehicle or CCl4 adminis-
tration (white bars) and 8 weeks of 
treatment followed by 4-week reso-
lution (black bars). Fibrosis was also 
determined by qRT-PCR for Col1a1 
and Acta2 (E and F). 3–4 animals per 
group. 1-way ANOVA with Tukey’s 
post-hoc test: *P < 0.05, **P < 0.01 
and ***P < 0.001 versus WT MO at 
8 weeks; †P < 0.05 and #P < 0.001 
versus WT MO at 12 weeks.
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patic CD11b+GR1+ cells compared with what was observed in WT 
animals fed an MCD diet (Figure 7, G and H).
Aoc3–/– and Ab-treated mice show reduced fibrogenesis in response 
to an MCD diet. Parenchymal infiltration by leukocytes drives the 
development of fibrosis in NAFLD (5, 42), leading us to investigate 
whether Aoc3–/– and Ab-treated mice are protected against fibrosis 
following 6 weeks of an MCD diet. Both VAP-1 deficiency and pro-
phylactic anti–VAP-1 Ab blockade resulted in significant and simi-
lar reductions in α-SMA expression (Figure 8, A and B) and collagen 
deposition (Figure 8, C and D) compared with that seen in WT mice 
when assessed by histological morphometric analysis and by qRT-
PCR of total Acta2 and Col1a1  mRNA from whole mouse liver (Fig-
ure 8E). We observed a similar pattern in WT mice that received 
therapeutic doses of anti–VAP-1 Ab for the last 4 weeks of the diet: 
the recruitment of CD11b+F4/80+ macrophages was significantly 
reduced in WT mice receiving anti–VAP-1 Ab, and this was associ-
ated with an attenuated fibrotic response (Figure 9, A and B).
animals on an MCD diet, we characterized changes in the 
infiltrate in detail at 6 weeks by quantifying and phenotyping 
liver-infiltrating leukocytes (Figure 7). WT mice fed an MCD 
diet showed a 2.2-fold increase in intrahepatic CD3+ T cells com-
pared with that seen in control mice that received normal chow 
(NC) (Figure 7A). The number of intrahepatic CD3+ T cells was 
significantly reduced in Aoc3–/– mice compared with that in WT 
animals due to a reduction in the numbers of intrahepatic CD4+ 
T cell and CD3+NK1.1+ NKT cell populations (Figure 7, B and E). 
In contrast to the CCl4 model, we found no significant differences 
in the expansion of intrahepatic CD8+ T cells (~4.5-fold increase 
vs. NC-fed mice) and CD19+ B cells (~1.7-fold increase vs. NC-fed 
mice) between WT and Aoc3–/– mice (Figure 7, C and F). MCD diet–
fed WT mice demonstrated a 4.4-fold increase in CD11b+F4/80+ 
macrophages and a 6.8-fold increase in CD11b+GR1+ monocytes 
compared with NC-fed mice. MCD diet–fed Aoc3–/– mice had sim-
ilar numbers of CD11b+F4/80+ macrophages but fewer intrahe-
Figure 5. Reduced leukocyte infiltration of the liver after CCl4 treatment in Aoc3–/– mice. The number of liver-infiltrating cells in WT or Aoc3–/– mice after 
CCl4 for 2, 4, or 8 weeks or following 8 weeks of CCl4 treatment followed by 4 weeks of resolution (Res) was quantified by flow cytometry. (A) There were 
significantly more T cells, B cells, NKT cells, and NK cells in WT animals (black bars) treated with CCl4 compared with those in Aoc3
–/– mice (white bars). Data 
are expressed as the number of infiltrating cells per gram of fresh liver tissue (A) or fold change over baseline (Base) values (B and C: upper panels: WT; lower 
panels: Aoc3–/–) for 3 to 5 animals per group. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 2-way ANOVA with Bonferroni’s correction.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
5 0 9jci.org   Volume 125   Number 2   February 2015
studied the pathological changes at 6, 9, and 12 months during 
evolution of NAFLD and compared these outcomes with mice fed 
NC and standard drinking water and allowed unrestricted activity.
Serum ALT levels were elevated in mice exposed to the WLM by 
6 months, but we observed no significant differences in ALT levels 
between WT or Aoc3–/– mice at either 6 or 9 months (Figure 10A). 
Aoc3–/– mice gained more weight during the first month of the diet 
compared with that seen in the WT group (Supplemental Figure 7).
Aoc3 expression was increased in WT mice following 9 
months of the diet when compared with that detected in animals 
on a NC diet (Figure 10A), and the extent of fibrosis at both the 
9- and 12-month time points was reduced in the Aoc3–/– animals, 
as evaluated by collagen deposition levels (Figure 10, B and C) 
and Acta2 and Col1a1 expression (Figure 10D). Although steato-
sis was present in all the WLM diet–fed animals, we found that 
the extent of steatosis was reduced in Aoc3–/– mice compared with 
that in WT mice at the 9-month time point (Figure 10, E and F). 
This was similar to what we observed with the MCD diet–fed 
mice (compare Figure 6).
We quantified immune cells isolated from the livers of WT and 
Aoc3–/– mice fed NC or those on the WLM diet at 6 and 9 months. 
We observed only a modest increase in CD8+ T cells, NK1.1+ cells, 
CD11b+F4/80+ cells, and Cd11b+GR1+ myeloid cells at 6 months, 
and there were no significant differences between WT and Aoc3–/– 
mice in the numbers of any cell type (Figure 11). However, by 9 
months, the WLM mice developed an inflammatory infiltrate com-
parable in profile and absolute cell numbers to what we observed 
in mice after 6 weeks on an MCD diet (compare Figures 7 and 11). 
Although the MCD diet model of steatohepatitis recapitulates 
many of the histological features of human NASH, it is an acute 
model resulting in weight loss and is not associated with systemic 
insulin resistance and as such does not mirror the physiological 
changes that occur during metabolic syndrome–induced human 
NAFLD. Thus, we felt it important to investigate the effects of 
VAP-1 deficiency in chronic models of steatohepatitis that are 
associated with obesity and insulin resistance.
C57BL/6 mice fed a high-fat diet (HFD) for 18 weeks develop 
obesity, glucose intolerance, hyperinsulinemia, hyperleptinemia, 
and hypercholesterolemia (43). The main hepatic pathology seen 
following an HFD is macrovesicular steatosis, with the develop-
ment of steatohepatitis and modest fibrosis after a prolonged HFD 
(44). We observed that WT mice fed an HFD for 18 weeks devel-
oped severe macrovesicular steatosis, inflammatory foci, and thin, 
fibrous septa, all of which were greatly reduced in Aoc3–/– animals, 
together with reduced Acta2 and Col1a1 expression (Supplemen-
tal Figures 3–6). Although the HFD model more closely resembles 
the pathophysiology of human NASH, the extent of steatohepatitis 
is not as severe as that seen with the MCD diet model (45). Tetri 
et al. described a murine model of steatohepatitis that develops in 
response to a diet high in trans fats and fructose and interventions 
to promote sedentary behavior (46). This Western lifestyle model 
(WLM) is characterized by obesity with impaired glucose toler-
ance and increased plasma insulin, resistin, and leptin compara-
ble to the pathological changes seen in NAFLD and at 16 weeks, 
animals develop severe steatosis with significant necroinflamma-
tory activity. We exposed WT and Aoc3–/– mice to this regimen and 
Figure 6. WT mice receiving anti–VAP-1 Ab (BTT-1029) and Aoc3–/– animals 
are protected against MCD diet–induced steatohepatitis. (A) Serum ALT 
levels of animals fed an MCD diet. (B and C) Inflammatory score based 
on sections stained with H&E, determined as: 0 = no foci per field, 1 = 1–2 
foci, 2 = 3–4 foci, 3 = >4 foci. 5 fields of view per animal. Scale bars: 50 μm. 
(D) Accumulation of lipid droplets in murine tissue sections was assessed 
by Oil red O staining (red) with hematoxylin counterstaining (blue) and 
expressed as a percentage of surface area occupied by the lipid (E, 5 fields 
of view per animal). 6 animals per group. Scale bars: 50 μm. ****P < 0.0001 
by 1-way ANOVA with Tukey’s post-hoc test (A and E) and ***P < 0.001 by 
Kruskal-Wallis test with Dunn’s multiple comparisons (C).
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reductions in hepatic CD4+ and NK1.1+ T cells 
as those seen in the Aoc3–/– mice (Figure 12), 
confirming that the amine oxidase activity of 
VAP-1 is involved in the generation of hep-
atitis in vivo. While mice with catalytically 
inactive VAP-1 had levels of injury similar to 
those seen in the WT mice at 4.5 weeks (Sup-
plemental Figures 9–12), catalytic inactiva-
tion of VAP-1 resulted in a significant loss of 
Acta2 expression at 6 weeks (Figure 12B), sug-
gesting that the reduced infiltrate results in an 
attenuated fibrotic response.
VAP-1 enhances wound healing by hepatic 
stromal cells in vitro. The presence of VAP-1 
protein within fibrotic septa of chronically 
diseased human liver tissue suggested that 
it might contribute to remodeling of the 
scar via direct effects on the hepatic stroma. 
Short-term (24-hour) treatment with sVAP-1 
at 500 ng/ml had no effect on aHSC acti-
vation, proliferation, or apoptosis in vitro 
based on detachment assays, cell prolifer-
ation measurements, and qRT-PCR for the 
prosurvival factor BCL2 and the associated 
proapoptotic factor BAX (Supplemental Fig-
ure 13). However, we observed increased cell 
spreading in impedance-based assays upon treatment with either 
sVAP-1 or a recombinant form of the protein produced in CHO 
cells (rVAP-1) (Figure 13A). The potent mitogen PDGF-BB had no 
effect on cell spreading over the same time course. This prompted 
us to investigate the effect of de novo synthesized VAP-1 on stro-
mal cell function. Overexpression of an N-terminal GFP-tagged 
form of VAP-1 (GFP-WT-VAP-1, described in ref. 47) in LX2 cells 
accelerated wound healing in a scratch wound assay when com-
pared with that in the control transfectant plasmid Lifeact-GFP 
(pLifeact-GFP), which is known to have little-to-no effect on cell 
motility (ref. 48 and Figure 13B). This effect was not dependent 
on enzyme activity, as expression of the enzyme-dead mutant of 
VAP-1 (GFP-Y471F-VAP-1) had a similar effect (Figure 13B). In 
complementary experiments, siRNA-mediated knockdown of 
AOC3 in LX2 cells retarded wound closure when compared with 
that seen in scrambled controls (Figure 13C).
Expression of VAP-1 regulates the transcription of profibrotic 
factors. To investigate the mechanism by which VAP-1 drives the 
fibrotic response, we measured the expression levels of genes 
associated with fibrosis in transfected LX2 cells by qRT-PCR. 
Moreover, VAP-1 deficiency was associated with reduced numbers 
of intrahepatic CD4+ and NK1.1+ T cell populations at 9 months. 
Thus, VAP-1 promotes a cellular infiltrate that precedes the devel-
opment of fibrosis.
The amine oxidase activity of VAP-1 promotes progression of 
steatohepatitis. Because we had demonstrated that VAP-1 SSAO 
activity is involved in lymphocyte chemotaxis and transendo-
thelial migration (12), we investigated the requirement for SSAO 
activity in the development of steatohepatitis. We generated 
mice in which WT Aoc3 was deleted and replaced by an Aoc3 
point–mutation knock-in (SSAO KO), in which the change of 
a single amino acid in the active site from Tyr to Phe renders 
VAP-1 catalytically inactive. These mice show a normal tissue 
distribution of VAP-1 with undetectable SSAO enzyme activity 
(Supplemental Figure 8).
Since the inflammatory changes in the MCD diet model were 
similar to those seen in the more relevant WLM, we used the 
shorter MCD diet model to study the development of steatohep-
atitis in SSAO-KO mice. Following 4.5 weeks of an MCD diet, 
the presence of catalytically inactive VAP-1 resulted in the same 
Figure 7. Aoc3–/– mice have fewer intrahepatic 
CD4+ and NK1.1+ T cells and CD11b+GR1+ monocytes 
compared with WT animals fed an MCD diet for 6 
weeks. Numbers and phenotype of liver-infiltrating 
cells per gram of fresh liver tissue from WT (black) 
and Aoc3–/– (blue) mice following 6 weeks of an 
NC or MCD diet were evaluated by flow cytometry. 
All cells were gated from a live CD45+ population 
isolated from livers perfused with PBS to deplete 
peripheral blood. 3–5 animals per group. *P < 0.05 
and ***P < 0.001 by Mann-Whitney U test.
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the inflammasome in response to liver injury (49–52). Steatohepa-
titis is characterized by infiltration of the hepatic parenchyma with 
T cells, macrophages, and neutrophils (53), and previous findings 
that VAP-1 plays an important role in the recruitment of lympho-
cytes and monocytes to the liver prompted us to study its role in 
NAFLD (12, 15, 39). We have reported that VAP-1 is shed into the 
circulation as a soluble enzyme that accounts for most of the circu-
lating monoamine oxidase activity in human blood and that levels 
are increased in chronic inflammatory liver diseases, but not in 
acute liver injury (23, 26). We now report elevated sVAP-1 levels 
in a well-defined cohort of NAFLD patients that is associated with 
increased VAP-1 expression in the liver. Because sVAP-1 levels are 
elevated in patients with obesity and type 2 diabetes, we compared 
these levels in NAFLD with those in a group of patients matched 
for BMI and metabolic phenotype who had no evidence of liver 
involvement. We found that sVAP-1 levels were elevated in the 
metabolic syndrome cohort compared with those in healthy con-
trols, but were significantly lower compared with levels in NAFLD 
patients. Circulating sVAP-1 levels also correlated with histological 
evidence of steatohepatitis and fibrosis on liver biopsy, and multi-
variate analysis showed that VAP-1 was independently associated 
with fibrosis stage. Reliable methods to assess steatohepatitis, 
Overexpression of AOC3 in cells transfected with GFP-tagged 
VAP-1 plasmid constructs was demonstrated by a 2,000-fold 
increase in message when compared with that in control cells 
transfected with Lifeact-GFP (Figure 14A). We found that expres-
sion of PDGFRB, which is a characteristic of HSC activation, 
was increased in GFP-WT-VAP-1–transfected cells, and this was 
dependent on the enzymatic activity of VAP-1, as the enzyme-
dead mutant (GFP-Y471F-VAP-1) did not elicit a similar response, 
suggesting that expression of catalytically active VAP-1 provides 
a profibrogenic stimulus. This hypothesis was supported by the 
observation that GFP-WT-VAP-1 induced upregulation of both 
COL1A1 and LOXL2 (Figure 14A), the latter being a related amine 
oxidase that has been implicated in the development of fibrosis in 
a number of disease models (38). We confirmed the close asso-
ciation between VAP-1 and the expression of profibrotic genes in 
siRNA-mediated knockdown experiments, in which reduced 
AOC3 expression in LX2  cells downregulated the expression of 
both COL1A1 and LOXL2 (Figure 14B).
Discussion
In NAFLD, the progression of steatosis to cirrhosis is driven by 
steatohepatitis, which develops as a consequence of activation of 
Figure 8. Administration of anti–VAP-1 Ab (BTT-1029) or deficiency of Aoc3 limits fibrosis in animals fed a 6-week MCD diet. Immunohistochemi-
cal staining for α-SMA (A and B) and Van Gieson’s collagen staining (C and D) were expressed as a percentage of the surface area of the field of view, 
calculated using ImageJ software (B, α-SMA; D, Van Gieson’s/collagen). 3–5 animals per group with 3 to 5 fields of view per animal. Scale bars: 50 μm. 
(E) Changes in Acta2 and Col1a1 mRNA expression in the liver tissue of these animals were quantified by qRT-PCR (4–5 animals per group). **P < 0.01, 
***P < 0.001, and ****P < 0.0001 by 1-way ANOVA with Tukey’s post-hoc test.
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are closely associated with sinusoidal endothelium and 
act as pericytes, contributing to the regulation of endo-
thelial differentiation and function (54). In response to 
injury, quiescent HSCs proliferate and transdifferenti-
ate into activated myofibroblasts, which deposit matrix 
during hepatic fibrogenesis. We found that both in vivo–
activated aLMFs and in vitro–activated HSCs expressed 
and secreted enzymatically active VAP-1, which was a 
potent leukocyte chemotactic factor at levels compa-
rable to those found in vivo. Thus, VAP-1 can modulate 
leukocyte migration in both its transmembranous and 
soluble forms. This property was dependent in part on 
SSAO activity associated with the generation of H2O2 
and, to our knowledge, is the first report of SSAO directly 
stimulating leukocyte motility. It is likely that VAP-1 pro-
duction by endothelial cells and myofibroblasts gener-
ates a local gradient of sVAP-1/H2O2, which stimulates 
leukocyte migration and recruitment. Our finding that 
the chemotactic effect of sVAP-1 was reduced by treat-
ment with pertussis toxin is consistent with a contribu-
tion from autocrine activation of chemotactic factors 
that signal through GPCRs, as has been described for 
neutrophils migrating in response to H2O2 (55). Autocrine 
chemoattractant production and direct modification of 
redox-sensitive intracellular receptors has been shown in 
monocyte migration in response to lysyl oxidase, another 
enzyme that generates H2O2 (56, 57). This model is con-
sistent with a study in zebrafish, in which a tissue gradi-
ent of H2O2 produced by an unidentified amine oxidase 
recruits leukocytes to the scar during wound healing (35). 
Thus VAP-1–generated H2O2 could operate in a similar 
way, resulting in a local tissue gradient that promotes and 
sustains the recruitment of leukocytes to the hepatic par-
enchyma. We suggest that endothelial VAP-1 promotes 
the recruitment of effector cells to the inflamed liver and 
that VAP-1 produced by HSCs positions them within the 
hepatic scar. These findings are consistent with, and pro-
vide a potential mechanism to explain, previous observa-
tions that VAP-1 expressed by specialized splenic fibroblasts guides 
lymphocyte migration within the spleen (58).
In order to test the hypothesis that VAP-1 links inflammation 
and fibrosis in response to liver injury, we compared the response 
to CCl4-induced liver injury in WT mice, Aoc3–/– animals, and WT 
mice treated with a neutralizing anti–VAP-1 Ab. In response to 
CCl4, WT mice developed septal fibrosis and increased leukocyte 
infiltration. The absence of VAP-1 in Aoc3–/– mice or its blockade 
by Ab in WT animals markedly reduced fibrosis and accelerated 
recovery in response to CCl4, implicating VAP-1 in fibrogenesis 
fibrosis, and the risk of progression to cirrhosis in NAFLD are lim-
ited. The current findings suggest that sVAP-1 levels, particularly 
if combined with other biomarkers of fibrosis, could have clinical 
utility as a noninvasive biomarker to differentiate between simple 
steatosis and NASH.
The association between sVAP-1 and fibrosis led us to inves-
tigate the expression of VAP-1 protein in patients with other types 
of CLD. Detailed studies revealed that VAP-1 was expressed by the 
hepatic stroma as well as by endothelial cells, and we observed no 
detectable staining of hepatocytes or cholangiocytes. Stellate cells 
Figure 9. Therapeutic administration of anti–VAP-1 Ab BTT-
1029 reduces hepatic leukocyte recruitment and fibrosis in 
WT mice fed an MCD diet for 6 weeks. (A) The proportion of 
leukocyte subsets relative to the live CD45+ cell population 
was assessed by flow cytometry. DX-5 is a pan-NK marker. (B) 
Changes in the expression of Acta2 and Col1a1 in the liver tis-
sue of these animals were quantified by qRT-PCR. 5–6 animals 
per group. **P < 0.01 by Mann-Whitney U test.
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fructose and trans-fat diet develop NASH 
over a 9- to 12-month period, we were able 
to study the kinetics of hepatitis and fibro-
sis development in a model that recapitu-
lates human NAFLD. Both WT and Aoc3–/– 
mice developed steatosis and liver injury, 
as measured by ALT levels after 6 months, 
before the development of steatohepatitis 
that developed between 6 and 9 months, 
and they developed fibrosis that was appar-
ent at 12 months. The severity of steatosis 
was reduced, though not abolished, in 
Aoc3–/– animals (similar to our findings with 
MCD diet– and HFD-fed mice), suggest-
ing that VAP-1 promotes steatosis as well 
as steatohepatitis. We expected this would 
be an SSAO-dependent effect of VAP-1, 
but surprisingly, steatosis was reduced by 
Ab treatment, which does not inhibit SSAO 
activity toward small conventional amine 
substrates, and was unaffected in mice 
expressing enzyme-dead VAP-1. The rea-
sons for this are currently unclear. VAP-1 
substrates have been shown to activate 
glucose transport (59), and feeding mice 
the SSAO inhibitor semicarbazide limits weight gain and inhibits 
fat deposition in adipose tissue (60). However, Bour et al. demon-
strated that Aoc3–/– animals have reduced leukocyte infiltration 
into white adipose tissue associated with increased fat deposition, 
which could not be rescued by expression of VAP-1 from the human 
adipocyte–specific aP2 promoter (61). These data suggest that the 
role of VAP-1 in the development of hepatic steatosis is complex and 
that the effects of adipocyte-specific VAP-1 on the release of adipok-
ines must also be taken into consideration.
Steatohepatitis in response to the WLM was characterized by 
a mixed inflammatory cell infiltrate that was markedly reduced 
in Aoc3–/– animals. The composition of the infiltrate showed a spe-
cific reduction in CD4 and NKT cells in the Aoc3–/– animals, and 
and fibrosis resolution. In the absence of VAP-1, the absolute 
numbers of both lymphoid and myeloid cells were substantially 
reduced, consistent with a model in which VAP-1 promotes the 
recruitment of an infiltrate that drives the development of fibrosis.
Several properties of VAP-1 SSAO suggest that it could have roles 
in NAFLD progression in addition to the ability to recruit inflamma-
tory cells. These include the local generation of ROS by SSAO activ-
ity and the ability of SSAO to sensitize insulin signaling. Our current 
data generated in 3 different models of NAFLD suggest that VAP-1 
contributes to the establishment of steatohepatitis and progression 
to fibrosis. This was evidenced by reduced inflammation, steatosis, 
and fibrosis in the absence of VAP-1 in an HFD, an MCD diet, and in 
the WLM. Using the WLM of NAFLD, in which mice given a high-
Figure 10. Liver tissue from Aoc3–/– animals 
exhibits reduced steatosis and fibrosis when 
fed a WLM diet. (A) Serum ALT levels of WT or 
Aoc3–/– animals fed either a NC or WLM diet for 6 
or 9 months and Aoc3 expression in WT animals 
at 9 months. 3–5 animals per group. (B) Collagen 
deposition in the WLM animals was visualized by 
Van Gieson’s staining at 9 and 12 months, and the 
surface area covered by the stain at the 12-month 
time point was evaluated by ImageJ software (C). 
5–6 animals per group; 5 fields per animal. Scale 
bars: 50 μm. (D) Changes in Acta2 and Col1a1 
expression in the liver tissue of these animals at 
12 months were quantified by qRT-PCR. 4–6 ani-
mals per group. (E and F) The extent of steatosis 
in WT and Aoc3–/– animals fed a WLM diet at 9 
months was evaluated by Oil red O staining and 
ImageJ software. 4 animal per group; 3–5 fields 
per animal. Scale bars: 50 μm. ***P < 0.001 and 
****P < 0.0001 by Mann-Whitney U test.
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activity (63), has been associated with a reduction in the 
risk of fibrosis in NASH patients (64). However, the fact 
that we were able to effectively prevent fibrosis using a 
VAP-1–blocking Ab that does not bind to the enzyme 
active site or inhibit deamination of small soluble sub-
strates in vitro suggests a more complex mechanism. It 
is possible that the Ab prevents access of endogenous, 
cell-associated macromolecular substrates to the enzyme 
in vivo, although until the endogenous ligands of murine 
VAP-1 are defined, it is difficult to test this hypothesis. 
An alternative explanation is that recruitment requires 
sequential interactions involving enzyme-dependent 
and -independent steps; if either of these is blocked, 
recruitment fails. A similar mechanism was proposed 
for the recruitment of granulocytes across endothelial 
monolayers (65). Both hypotheses are consistent with 
our murine data and suggest that both VAP-1–blocking 
Abs and enzyme inhibitors have therapeutic potential.
We used wound-healing and transfection stud-
ies to examine the direct effects of VAP-1 expres-
sion on the stromal cell population. VAP-1 promoted 
the wound-healing response, induced spreading 
of aHSCs, and enhanced expression of profibrotic 
genes (COL1A1, LOXL2), indicating that VAP-1 has 
direct effects on stellate cells that could promote scarring. There 
is a precedent for the involvement of VAP-1 in matrix remodel-
ing, because its overexpression in arterial smooth muscle cells 
increases elastin deposition in the arterial wall (66). The con-
tribution of SSAO activity to these functions remains unclear, 
however, since accelerated wound healing was independent of 
enzyme activity, whereas expression of profibrotic genes was 
unaffected by the transfection of LX2 cells with a catalytically 
inactive form of the protein (Figures 13 and 14). A similar effect 
has been observed for LOXL2, in which enzyme-dead forms of 
the protein retained function (67, 68).
We suggest that VAP-1 plays a complex role in the pathogene-
sis of CLD. Its ability to promote the recruitment of leukocytes to 
the liver in response to initial liver injury and its contribution to the 
development of fibrosis suggest that targeting VAP-1 therapeuti-
cally, through Ab blockade or enzyme inhibitors, could prevent the 
progression of liver disease.
Methods
Study populations. Serum from NAFLD patients (n = 133) was obtained at 
the time of the patient’s admission for liver biopsy. All patients included 
in the study had histologically confirmed NAFLD, with biopsies graded 
these mice failed to develop significant fibrosis at 12 months. The 
changes in infiltrate were very similar to those seen in the MCD 
diet–induced model of steatohepatitis, in which we also observed 
a reduction in CD4 and NKT cell infiltration and a subsequent 
reduction in fibrosis in Aoc3–/– animals. The shorter time frame of 
the MCD diet model allowed us to show that we could achieve sim-
ilar effects in WT animals using an anti–VAP-1–blocking Ab with 
both prophylactic and therapeutic dosing strategies.
As VAP-1 has both enzyme and adhesive properties, we deter-
mined whether the effect of VAP-1 on leukocyte recruitment was 
dependent on SSAO activity. Because there are limited highly 
specific enzyme inhibitors for murine SSAO, we generated a mouse 
in which native Aoc3 was replaced by a mutated Aoc3, in which a sin-
gle conservative (Tyr to Phe) amino acid change renders the mole-
cule enzymatically inactive. We showed that the mutant protein was 
expressed with the same tissue distribution as that of WT VAP-1, 
consistent with a recent report (62), and then subjected the mice 
to an MCD diet. Analysis of the infiltrate and expression of fibrotic 
genes showed a pattern of changes similar to that observed in 
Aoc3–/– animals, suggesting that SSAO activity contributes to 
VAP-1–mediated steatohepatitis and fibrosis in NAFLD. This is con-
sistent with the finding that caffeine, an inhibitor of amine oxidase 
Figure 11. Intrahepatic leukocyte populations are increased 
in animals fed a WLM diet for 9 months but not 6 months, 
with fewer CD4+ and NK1.1+ T cells present in Aoc3–/– mice 
fed a WLM diet for 9 months. The numbers and phenotype of 
liver-infiltrating cells per gram of fresh liver tissue from WT 
and Aoc3–/– mice following 6 and 9 months of  a NC or WLM 
diet were evaluated by flow cytometry. All cells were gated 
from a live CD45+ cell population isolated from livers perfused 
with PBS to deplete peripheral blood. 2–4 animals per group. 
For clarity, only the Mann-Whitney U tests between WT and 
Aoc3–/– at 9 months are shown; *P < 0.05.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
5 1 5jci.org   Volume 125   Number 2   February 2015
NHS Foundation Trust and the Newcastle-Upon-
Tyne Hospitals NHS Foundation Trust. Liver tis-
sue from explanted livers was taken from normal 
organ donor liver tissue that was surplus for surgical 
requirements or from uninvolved liver removed at 
hepatic resection for secondary liver tumors; dis-
eased tissue was obtained from patients undergoing 
liver transplantation for CLD.
Isolation of human HSCs and aLMFs and main-
tenance of the LX2 cell line. HSCs were isolated from 
nonfibrotic human liver tissue, and aLMFs were 
purified from fibrotic tissue as described previously 
(69). Cell viability was confirmed using trypan blue 
exclusion, and autofluorescence of HSCs suggested a 
greater than 90% purity. Cells were plated on plastic 
in DMEM containing 16% FCS (Invitrogen) and used 
within 4 passages. HSCs that adhered to plastic after 
isolation were termed aHSCs to differentiate them 
from their quiescent phenotype.
The HSC line LX2 (a gift of S. Friedman, Mount 
Sinai School of Medicine, New York, New York, 
USA) was maintained in DMEM containing 2% 
FCS (Invitrogen).
Soluble VAP-1 measurements. Soluble VAP-1 levels 
in human serum were measured by time-resolved 
immunofluorometric assay at Biotie Therapies Corp. 
Briefly, a biotin-conjugated monoclonal anti–VAP-1 
Ab (clone TK8-14; eBioscience) was immobilized 
onto a streptavidin-coated microtiter plate, to which 
the serum samples were added. sVAP-1 that had bound to the plate 
was then detected with a europium-conjugated anti–VAP-1 Ab (clone 
TK8-18; eBioscience). VAP-1 levels were measured by time-resolved 
fluorescence at 615 nm (VICTOR2 Multilabel Counter; PerkinElmer). 
Quantification of VAP-1 concentration in serum was based on a ref-
erence sample of highly purified human serum VAP-1 (Biovian Ltd.). 
The calibration range of the method was from 1.5 to 1,500 ng/ml. The 
linearity (R2) of the calibration (standard) curves was 0.997–1.000.
Cell migration assay. Chemotaxis assays were performed as previ-
ously described (70). Briefly, 30 μl aHSC-conditioned medium, highly 
purified sVAP-1 (Biotie Therapies Corp.), or recombinant CXCL12 
(10 ng/ml; Peprotech) was placed in the lower wells of a custom-made 
48-well chemotaxis chamber (Neuro Probe) separated from an upper 
chamber containing cell suspension (peripheral blood leukocytes, 
and staged according to the Kleiner classification; extensive clinical 
and biochemical characteristics were recorded at the time of biopsy 
(Table 1). A control cohort matched for age, BMI, and metabolic phe-
notype was established and fasting serum samples and anthropometric 
data collected (n = 74, Table 1). Exclusion criteria for all patients were: 
age of less than 18 years, consumption of greater than 20 g ethanol per 
day if female and greater than 30 g per day if male, infection with viral 
hepatitis or HIV, treatment with corticosteroids or immunosuppressive 
therapy within the past 12 weeks, and treatment with monoamine oxi-
dase inhibitors. Further exclusion criteria for the control cohort were 
biochemical or radiological evidence of liver disease. Serum was stored 
at –80°C until later use.
Human tissue. Human tissue and blood samples were collected 
from patients admitted to the University Hospitals Birmingham 
Figure 12. Mice harboring an enzyme-dead mutant 
of Aoc3 (SSAO KO) show reduced hepatic infiltration 
of leukocytes and reduced fibrosis compared with 
WT animals fed an MCD diet. (A) The numbers and 
phenotype of liver-infiltrating cells per gram of fresh 
liver tissue from WT and SSAO-KO mice following 4.5 
weeks of an MCD diet were evaluated by flow cytome-
try. All cells were gated from a live CD45+ cell popula-
tion isolated from livers perfused with PBS to deplete 
peripheral blood. 4–5 animals per group. (B) Changes in 
the expression of Acta2 and Col1a1 in the liver tissue of 
these animals were quantified at 6 weeks by qRT-PCR. 
5–6 animals per group. *P < 0.05 and **P < 0.01 by 
Mann-Whitney U test.
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
5 1 6 jci.org   Volume 125   Number 2   February 2015
100 U/ml catalase (Sigma-Aldrich) was included in the test wells to 
assess the contribution of H2O2; in others, the enzyme activity of VAP-1 
was inhibited by preincubation with 2.5 mM BEA (Sigma-Aldrich) for 
30 minutes prior to the assay.
Cellular proliferation assays. A CyQUANT NF Cell Proliferation 
Assay Kit (Invitrogen) was used to measure the total nucleic acid 
content of aHSCs after 8 days in culture in the absence and pres-
ence of 10 ng/ml PDGF-BB (Peprotech) or 500 ng/ml highly puri-
fied serum–derived sVAP-1 (Biotie Therapies Corp.) according to 
the manufacturer’s instructions.
Cellular attachment assay. Activated HSCs were seeded onto plates 
and allowed to adhere for 24 hours in DMEM containing 16% FCS in 
the presence of 1.5 μM gliotoxin (Sigma-Aldrich) or sVAP-1 (500 ng/ml) 
at 37°C and 5% CO2. Adherent cells were counted in 12 high-power 
fields and normalized to the cells receiving media alone. The data rep-
resent 3 separate aHSC isolates measured in triplicate.
1.5 × 106 cells/ml) by a polycarbonate membrane (5-μm pores, Nucle-
opore Filtration; Neuro Probe). Negative controls containing media 
alone or media containing inhibitor alone were included in each assay. 
The assembled chamber was incubated for 2 hours at 37°C in a humid-
ified CO2–enriched atmosphere. Following incubation, the filter was 
removed from the chamber and nonmigrated cells on the upper sur-
face removed by wiping before being air dried, fixed in methanol, and 
stained with hematoxylin (Diff-Quik; Sigma-Aldrich). The number of 
stained cells in 4 high-power fields (×40) for each of 6 wells per sample 
was counted, giving 24 fields of view per condition, and migration was 
calculated as the median of these 24 counts expressed as the number 
of migrating cells per high-power field. To assess the contribution of 
GPCR, leukocytes were pretreated with 100 ng/ml pertussis toxin 
(PTx; Sigma-Aldrich) for 30 minutes at 37°C, washed, and resus-
pended in RPMI containing 0.1% BSA prior to the assay. The viability 
of the leukocytes was not affected by this treatment. In some assays, 
Figure 13. VAP-1 induces spreading of aHSCs and promotes wound healing in LX2 cells independently of enzyme activity. (A) Treatment of aHSCs with 
soluble rVAP-1 or highly purified serum-derived VAP-1 (sVAP-1) induced cell spreading as assessed by xCELLigence impedance assay. Responses to sVAP-1, 
rVAP-1 (both 500 ng/ml), and PDGF-BB (10 ng/ml) were measured (n = 2, each measured in quadruplicate). (B) Transfection of LX2 with plasmids encoding 
WT or enzyme-dead (Y471F) VAP-1 enhanced wound healing when compared with that observed in control transfectants (Lifeact). Representative image from 
1 experiment is shown, with data taken from 3 independent experiments. (C) Conversely, knockdown of AOC3 gene expression with siRNA retarded wound 
closure when compared with that detected in scrambled control siRNA sequences. Representative image from 1 experiment is shown, with data taken from 3 
independent experiments. *P < 0.05, and **P < 0.01 by 1-way ANOVA with Tukey’s post-hoc test (A) and 2-way ANOVA with Bonferroni’s correction (B and C) .
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onic,  the contract breeder. Aoc3 point–mutation 
knock-in mice were backcrossed onto a C57BL/6 
genetic background by genOway and supplied by 
the contract breeder Charles River Laboratories. 
Mutant allele mice were identified by PCR screen-
ing of purified genomic DNA with specific primers.
CCl4 model. Female mice were injected 
twice weekly for 2, 4, 6, or 8 weeks with either 
CCl4 (1.0 ml/kg CCl4 diluted 1:4 in MO; Sigma- 
Aldrich) or MO alone. Animals were sacrificed 
96 hours after the final dose of CCl4. In parallel 
experiments, animals received vehicle or CCl4 
for 8 weeks, as above, at which point vehicle or 
CCl4 treatment was stopped, and the animals 
were sacrificed following 4 weeks of resolution.
Animal diets. MCD diet: Male mice were fed an 
MCD diet (MP Biomedicals) ad libitum for 4.5 to 6 
weeks. HFD: Male mice were fed an HFD diet that 
provided 55% of calories from fat (Special Diets 
Services) ad libitum for 18 weeks. WLM diet: Male 
mice were fed a diet with 45% of calories obtained 
from fat and 30% of the fat in the form of partially 
hydrogenated vegetable oil (Custom Research Diet 
TD.06303; Harlan Laboratories) in conjunction 
with fructose-supplemented drinking water (55% fructose, 45% glucose 
by weight at a concentration of 42 g/l) ad libitum for 6, 9, or 12 months. 
Control animals received NC and nonsupplemented drinking water.
Animals treated with the VAP-1 function–blocking Ab (mouse 
anti-mouse BTT-1029, 9 mg/kg; Biotie Therapies Corp.) received a) 
prophylactic weekly i.v. injections 1 week prior to and weekly through-
out the experiment, or b) therapeutic twice-weekly i.v. injections for 
the final 4 weeks of the 6-week experiment. BTT1029 is a mouse 
IgG2a mAb generated in Aoc3–/– animals by immunizing with human 
recombinant VAP-1. The Ab was selected from several hybridomas 
recognizing recombinant human VAP-1. A secondary screening was 
made to select antibodies that bound to recombinant mouse VAP-1 
(Biotie Therapies Corp.).
Blood samples were withdrawn by cardiac puncture during isofluo-
rane anesthesia, after which the mice were sacrificed by cervical disloca-
tion. Livers were dissected and processed for paraffin embedding, cryo-
sectioning, and RNA extraction (stored in RNAlater; QIAGEN). Bilirubin 
and ALT were measured at the clinical biochemistry laboratory of the 
Women’s Hospital Birmingham (Birmingham, United Kingdom), and 
serum glucose concentrations were obtained using Accu-Chek (Roche).
Cell-spreading assay and xCELLigence impedance measurements. 
The xCELLigence system was used according to the manufactur-
er’s instructions (Roche Applied Science) to measure the impedance 
every minute for 4 hours of a monolayer of 10,000 aHSCs per well 
in a pre-equilibrated E-Plate using integrated software. Data were 
normalized at the 40-minute time point to produce a dimensionless 
normalized cell index (NCI), and cell spreading was calculated using 
real-time cell analyzer (RTCA) software (Roche Applied Science). Two 
independent isolates of aHSCs were studied, with each treatment 
measured in quadruplicate.
Murine models of liver injury. All mice were maintained and housed 
under conventional conditions in the Biomedical Services Unit at the 
University of Birmingham or at the University of Turku. Up to 5 mice 
were housed per cage under alternating 12-hour light/12-hour dark 
cycles at 23°C. WT C57BL/6 (WT), Aoc3–/–, and Aoc3 point–mutation 
knock-in mice (SSAO KO, harboring a mutation in the sequence for 
an active site tyrosine to render the protein catalytically inactive) aged 
6 to 8 weeks were used in the studies. C57BL/6 mice were obtained 
from Charles River Laboratories. Aoc3–/– mice were re-derived from 
the previously described Aoc3–/– line (37) by blastocyst transfer at Tac-
Figure 14. VAP-1 is associated with the expression of 
fibrosis-associated genes in transfected LX2 cells. 
(A) Overexpression of WT but not enzyme-dead 
(Y471F) VAP-1 in LX2 cells led to a significant increase 
in COL1A1, PDGFRB, and LOXL2 expression at 72 
hours when compared with that in control transfec-
tants (Lifeact). (B) Knockdown of AOC3 in LX2 cells 
significantly reduced the expression of COL1A1 and 
LOXL2 at 72 hours following nucleofection. Data are 
representative of 2 experiments, each conducted in 
triplicate. *P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001 by 1-way ANOVA with Tukey’s post-
hoc test (A) and unpaired Student’s t test (B).
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a Prestige rabbit anti–human VAP-1 polyclonal Ab (HPA000980, 
1:200; Sigma-Aldrich), a Vector ImmPRESS secondary reagent kit, 
and NovaRED as a chromogen (both from Vector Laboratories). 
Immunohistochemistry on frozen sections taken from patients who 
underwent transplantation for end-stage CLD (alcoholic liver dis-
ease, primary biliary cirrhosis, primary sclerosing cholangitis) was 
performed in a similar manner using TK8-14 as the anti–VAP-1 Ab 
(BMS1033; eBioscience).
Immunofluorescence. Fresh-frozen, acetone-fixed tissue or 4% 
paraformaldehyde-fixed cells were incubated for 1 hour at room 
temperature with PBS containing 0.1% Triton X-100 and 10% goat 
serum (serum-PBST). Following overnight incubation with primary 
Abs against the antigens α-SMA (clone 1A4, 5 μg/ml; Sigma-Aldrich); 
CD31 (clone 9G11, 20 μg/ml; R&D Systems); VAP-1 (clone TK8-14, 
2.5 μg/ml; Biotie Therapies Corp.); VAP-1 (clone 174-5, 2 μg/ml; Novus 
Biologics); EpCAM (clone HEA125, 100 μg/ml; Progen); CK18 (clone 
DC10, 1 μg/ml; Dako); CD90 (clone 5E10, 1 μg/ml; eBioscience); CD3 
(clone UCHT1, 1 μg/ml; AbDSerotec); and CD68 (clone KP1, 1 μg/ml; 
Abcam), samples were washed 3 times in PBST and incubated with 
Alexa Fluor–conjugated secondary Abs (1:500; Invitrogen) for 1 hour 
at room temperature. Nuclei were visualized using DAPI nucleic acid 
stain (Invitrogen). Fluorescence images were acquired using a Zeiss 
LSM 510 confocal fluorescence microscope (ZEISS).
Quantification of liver-infiltrating immune cells. Mouse livers 
were harvested and perfused with PBS via cardiac puncture follow-
ing disconnection of the hepatic portal vein. The organs were then 
weighed, dissociated in a gentleMACS C Tube (Miltenyi Biotec), and 
the resulting immune cells were then purified and analyzed by flow 
cytometry. Inflammatory cells were gated as a CD45+ cell population 
(anti–CD45-PerCP-Cy5.5, clone 30-F11; BD Biosciences), and non-
viable cells were excluded using a LIVE/DEAD fixable stain (Invit-
rogen). Lymphocytes were characterized based on staining using 
a cocktail of anti–CD3-Pacific blue (clone 500A2); anti–CD4-PE 
(clone RM4-5); anti–CD8a-APC (clone 53-6.7); anti–CD19-APC-Cy7 
or anti–CD19-BV510 (both clone 1D3); and anti–NK1.1-FITC (clone 
PK136) or DX5-FITC (clone DX5) Abs (all from BD Biosciences), 
while the monocyte subsets were identified by staining with anti–
CD11b-PE (clone M1/70; BD Biosciences); anti–GR1-APC (clone 
RB6-8C5; BD Biosciences); and anti–F4/80-FITC (clone BM8; eBio-
science) Abs. Absolute cell counts were determined with AccuCheck 
Counting Beads (Invitrogen), and the number of cells was normal-
ized to the total liver weight. Data were analyzed using a CyAn ADP 
flow cytometer (Beckman Coulter) or a BD LSRII using Summit ver-
sion 4.3 or FlowJo version 10.0.7 software where appropriate.
Determination of amine oxidase activity in murine tissues and human 
serum samples. SSAO activity from human sera was measured as previ-
ously described (31). Briefly, 2.4 μl serum was incubated in the absence 
or presence of the SSAO inhibitor hydroxylamine (5 μM) for 30 min-
utes prior to the addition of SSAO substrate (benzylamine, 0.5 mM), 
HRP,  and Amplex Red reagent (Molecular Probes). The SSAO-depen-
dent production of hydrogen peroxide was followed for 60 minutes 
using a Tecan Infinite M200 spectrofluorometer. A calibration curve 
of exogenously added hydrogen peroxide was used to normalize the 
data. The SSAO activities in sera are reported as nmol hydrogen per-
oxide produced by 1 ml serum in 1 hour. SSAO activity from mouse fat 
lysates was measured as previously described (37). Briefly, fat tissue 
was lysed in PBS containing 0.2% NP-40. Protein concentrations were 
qRT-PCR. Total cellular RNA was isolated using an RNeasy kit 
(QIAGEN). RNA concentration and purity were measured using a Nano-
photometer (Geneflow Ltd.) or a Nanodrop 1000 (Thermo Scientific), 
and 1 μg of total RNA was transcribed to cDNA using the First Strand 
Synthesis Kit (Roche) or SuperScript III System (Invitrogen). Real-time 
PCR was carried out on each sample in triplicate using a Roche Lightcy-
cler 480 machine and Probes Master Mix (200 nM probe, 500 nM prim-
ers; Roche Diagnostics) or TaqMan Assay Mix (Invitrogen), as detailed 
in Supplemental Table 3. Cycling conditions were as follows: 95°C for 
10 seconds, 55–60°C (target dependent) for 50 seconds, and 72°C for 1 
second. For relative quantification analysis, data were normalized to the 
appropriate housekeeping gene using “E-analysis” (Roche Diagnostics) 
and the device software (version 1.5.0.39). Relative expression levels are 
shown as fold change compared with the appropriate unstimulated con-
trol, tissue, or animal. For absolute quantification studies, the number of 
copies of AOC3 mRNA in matched amounts of starting total RNA from 
each cell type was determined from a calibration curve of known dilu-
tions of a plasmid encoding AOC3.
Histopathology and immunohistochemistry. For morphological 
analysis, murine liver specimens were fixed in 4% paraformalde-
hyde, embedded in paraffin, and cut into 4-μm sections. Slides were 
deparaffinized according to standard procedures and stained with 
freshly made H&E. To evaluate fibrosis, the sections were stained 
with Van Gieson’s solution (Sigma-Aldrich) or Picosirius Red 
(Sigma-Aldrich) staining according to standard protocols. For semi-
quantitative determination of hepatic infiltrate, 5 random fields of 
H&E-stained sections at 20× objective magnification were assessed 
per animal. Inflammatory scores were determined as follows: 
0 = no foci per field; 1 = 1–2 foci; 2 = 3–4 foci; 3 = >4 foci. For VAP-1 
staining in murine tissue, acetone-fixed sections were sequentially 
incubated with an anti–VAP-1 mAb (TK7-88; ref. 71) and HRP-con-
jugated anti–rat Ig (Dako). Immunoreactivity was visualized using 
DAB as a chromogen. The sections were counterstained with hema-
toxylin, and micrographs were acquired using an Olympus BX60 
microscope and the Cell D program.
Oil red O staining of freshly cut sections of murine liver tissue 
(7-μm thickness) was carried out to evaluate the extent of steatosis. 
Sections were incubated in 60% propan-2-ol for 5 minutes, followed by 
a 15-minute incubation with Oil red O reagent (0.3% Oil red O in pro-
pan-2-ol/water; Sigma-Aldrich). Next, the samples were washed with 
propan-2-ol, then water, and mounted in Immunomount (Fisher Sci-
entific). A Mouse-on-Mouse kit (Vector Laboratories) was used in con-
junction with an anti–α-SMA mAb (clone 1A4, murine IgG2a, 5 μg/ml; 
Sigma-Aldrich) to detect α-SMA in 7-μm-thick tissue slices. The stain-
ing was visualized with a VECTASTAIN Elite ABC kit and NovaRed 
substrate (Vector Laboratories). Determination of the surface area cov-
ered by the stain was performed by analysis of  3 to 5 random fields per 
animal (depending on the size of the section) at ×20 magnification and 
threshold analysis with ImageJ software version 1.42q (NIH).
Human tissue samples (10 × 10 × 5 mm) were taken from livers 
exhibiting a normal phenotype, mild steatosis, moderate steato-
sis, severe steatosis, or cirrhosis (4 individuals per group, based on 
histology of hematoxylin-stained tissue sections as assessed by a 
trained pathologist [SGH]). These samples were fixed in formalin 
and processed through to paraffin wax. Tissues were deparaffinized 
and rehydrated to water and, after a low temperature retrieval tech-
nique (ALTER), were immunostained on a Dako Autostainer using 
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Two-tailed Student’s t tests were used when appropriate. A P value 
of less than 0.05 was considered significant.
Study approval. Serum and tissue samples from patients were 
obtained with written informed consent and with local ethics com-
mittee approval (LREC references 10/H0906/41, Newcastle & North 
Tyneside 1, UK; 04/Q2707/278, South Birmingham, Birmingham, 
UK; 06/Q2702/61, South Birmingham, Birmingham, UK; 98/CA5192, 
South Birmingham, Birmingham, UK; 04/Q2708/41, South Birming-
ham, Birmingham, UK). Animal studies were performed in accordance 
with the UK Animals (Scientific Procedures) Act of 1986, with approval 
granted by the UK Home Office (project license PPL 40/3201, Shrews-
bury office) and with approval of the IACUC of the State Provincial 
Office of Southern Finland and in compliance with Finnish laws relat-
ing to the conduct of animal experimentation.
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determined from clarified lysates, and 30 μg lysate was subjected to 
Amplex Red assays as described above.
Transfection of cells with siRNA or plasmid DNA encoding GFP 
fusion proteins. Cells were transiently transfected with plasmid DNA 
or siRNA using a Nucleofector II (Lonza) according to the manu-
facturer’s instructions. Briefly, 5 μg DNA or 500 nM siRNA (AOC3 
silencer from Invitrogen; s16435, sense: 5′-AGACUAGUUUAUGA-
GAUAATT-3′, antisense: 5′-UUAUCUCAUAAACUAGUCUTT-3′; 
silencer controls 1 and 2 from the same company were used as non-
targeting siRNA) was nucleofected into 1.0 × 106 cells in 100 μl basic 
fibroblast Nucleofection solution (Lonza) using program A-023. The 
plasmids coding for GFP-WT-VAP-1 and the enzyme-dead mutant 
GFP-Y471F-VAP-1 have been previously described (47). Lifeact-GFP 
was obtained from Thistle Scientific.
Monitoring wound closure with the Cell-IQ system. Real-time cell 
images of scratch wound assays were captured by a Cell-IQ system 
(CM Technologies) running Imagen software version 2.8.12.0 and 
analyzer version 3.3.0. For scratch wound assays, cells were trans-
fected with the appropriate plasmid or siRNA and plated at a cell 
density of 100,000 cells per well (diluted in DMEM containing 2 % 
FCS, 1 ml per well) in a 24-well plate. Following overnight incuba-
tion, the media were replaced, and the cells were incubated for an 
additional 24 hours to reach confluence. A scratch wound was then 
effected using a 200-μl capacity pipette tip, and the media were 
replaced. The well plate was then inserted into the Cell-IQ, and the 
closure of each wound was monitored over a 24-hour period in a 5% 
CO2 and air environment maintained at 37°C.
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